

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
華康生物醫學控股有限公司
(Incorporated in Cayman Islands with limited liability)
(Stock Code: 8622)

**EXTENSION OF LONG STOP DATE OF
PLACING OF NEW SHARES UNDER GENERAL MANDATE**

Placing Agent



長雄證券有限公司
EVER-LONG SECURITIES COMPANY LIMITED

Reference is made to the announcements of Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 29 July 2022 and 5 August 2022 (the “**Announcements**”) in respect of the Placing. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

EXTENSION OF LONG STOP DATE

As additional time is required for fulfilment of the conditions under the Placing Agreement dated 29 July 2022, the Company and the Placing Agent, after arm’s length negotiation, have entered into a second supplemental placing agreement (the “**Second Supplemental Placing Agreement**”) on 18 August 2022 (after trading hours). Pursuant to the Second Supplemental Placing Agreement, the Long Stop Date of the Placing Agreement is extended from 19 August 2022 to 2 September 2022 (or such later date as may be agreed between the parties).

Save for the aforesaid amendment under the Second Supplemental Placing Agreement, there is no other change to the Placing Agreement and all other terms and conditions of the Placing Agreement shall continue to remain in full force and effect.

Shareholders and potential investors should note that the Completion is subject to conditions under the Placing Agreement to be fulfilled. As the Placing may or may not proceed, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 18 August 2022

As at the date of this announcement, the executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the independent non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.